During the last years, we have established a murine model for allergic asthma tothe major cat allergenFel d 1 that we used to test CpG-based specific immunotherapy. We have shownthat the allergic response to Fel d 1 was significantly reduced in mice undergoing CpG-driven immunotherapy (manuscript in preparation). Unexpectedly, the secretion of TNF was observed in the broncho-alveolar lavages of the treated mice. The TNF-TNFR2 interaction plays a critical role in the generation, expansion and function of human and mouse Tregsand defects in TNFR2 signaling have been found in many autoimmune disorders .However, so far, no TNF dependent mechanism has been described in allergy immunotherapy treatments, in which the accent is invariably stressed on the suppressor cytokines IL-10 and TGF-β. On basis of the Fel d 1 SIT model, we aim to gain in understanding the pathwaysand networksinduced by CpG triggering and the role of TNF in the stimulation of (unconventional) Tregs.We will utilize TNFKO and TNFR2KO mouse strains, as well as conditional TNFKO miceand analyze various cellular types, measure various layers of ‘omics’ in sorted T cell subsets following the course of allergy induction and CpG treatment.
|Acronym||NEXTIMMUNE (Guillem Montamat)|
|Effective start/end date||15/01/17 → 14/01/21|
- FNR - Fonds National de la Recherche: €169,500.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.